<DOC>
	<DOCNO>NCT00664963</DOCNO>
	<brief_summary>The purpose study compare effectiveness treatment balloon-expandable YUKON-BTX-Sirolimus-eluting stent treatment YUKON-BTX uncoated stent patient ischemic infrapopliteal arterial disease .</brief_summary>
	<brief_title>YUKON-drug-eluting Stent Below The Knee - Randomised Double-blind Study</brief_title>
	<detailed_description>Based fact drug elute stent proven reduce restenosis rate coronary artery , assume YUKON-BTX-Sirolimus-eluting stent superior restenosis rate compare treatment uncoated stent below-the-knee artery consecutively . The purpose study compare restenosis rate treatment balloon-expandable YUKON-BTX-Sirolimus-eluting stent treatment YUKON-BTX uncoated stent patient ischemic infrapopliteal arterial disease . Randomisation perform extremity , may lead vary treatment within one patient study .</detailed_description>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Clinical diagnosis peripheral arterial occlusive disease define Rutherford 25 Denovo stenosis &gt; 70 % diameter stenosis tibioperoneal trunc , anterior and/or posterior tibial and/or peroneal artery Target lesion length â‰¤ 45 mm Coagulation disorder Known allergy contrast medium Contraindications antiplatelet therapy heparin</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Arterial Occlusive Diseases</keyword>
	<keyword>Peripheral Vascular Diseases</keyword>
	<keyword>Drug elute stent</keyword>
	<keyword>Restenosis</keyword>
	<keyword>Below knee</keyword>
	<keyword>Intervention</keyword>
</DOC>